Cognition Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
Cognition Therapeutics, Inc. (CGTX) reported Basic Shares Outstanding (Weighted Average) of 90.62 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-07
- Cognition Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 90.62M shares, a 42.29% increase year-over-year.
- Cognition Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 89.19M shares, a 44.26% increase year-over-year.
- Cognition Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 88.60M shares, a 98.31% increase year-over-year.
- Cognition Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 77.95M shares, a 92.86% increase year-over-year.
- Cognition Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 72.77M shares, a 83.15% increase from fiscal 2024.
- Cognition Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 39.73M shares, a 32.31% increase from fiscal 2023.
- Cognition Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 30.03M shares, a 27.03% increase from fiscal 2022.
- Cognition Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 23.64M shares, a 355.42% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 90.62M shares 10-Q · filed 2026-08-07 | 89.91M shares 10-Q · filed 2026-08-07 | 89.47M shares derived: average of 3 quarters · filed 2026-08-07 | 86.59M shares derived: average of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | 89.19M shares 10-Q · filed 2026-05-08 | 88.90M shares derived: average of 2 quarters · filed 2026-05-08 | 85.25M shares derived: average of 3 quarters · filed 2026-05-08 | 79.86M shares derived: average of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | 88.60M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 83.28M shares derived: average of 2 quarters · filed 2026-03-26 | 76.75M shares derived: average of 3 quarters · filed 2026-08-07 | 72.77M shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 77.95M shares 10-Q · filed 2025-11-06 | 70.82M shares derived: average of 2 quarters · filed 2026-08-07 | 67.49M shares 10-Q · filed 2025-11-06 | 62.04M shares derived: average of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | 63.69M shares 10-Q · filed 2026-08-07 | 62.17M shares 10-Q · filed 2026-08-07 | 56.73M shares derived: average of 3 quarters · filed 2026-08-07 | 52.65M shares derived: average of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | 61.83M shares 10-Q · filed 2026-05-08 | 53.25M shares derived: average of 2 quarters · filed 2026-05-08 | 48.97M shares derived: average of 3 quarters · filed 2026-05-08 | 46.75M shares derived: average of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | 44.68M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 42.55M shares derived: average of 2 quarters · filed 2026-03-26 | 41.72M shares derived: average of 3 quarters · filed 2026-03-26 | 39.73M shares 10-K · filed 2026-03-26 |
| 2024-09-30 | 40.42M shares 10-Q · filed 2025-11-06 | 40.24M shares derived: average of 2 quarters · filed 2025-11-06 | 38.08M shares 10-Q · filed 2025-11-06 | 36.31M shares derived: average of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | 40.06M shares 10-Q · filed 2025-08-07 | 36.90M shares 10-Q · filed 2025-08-07 | 34.94M shares derived: average of 3 quarters · filed 2025-08-07 | 33.80M shares derived: average of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | 33.74M shares 10-Q · filed 2025-05-07 | 32.38M shares derived: average of 2 quarters · filed 2025-05-07 | 31.71M shares derived: average of 3 quarters · filed 2025-05-07 | 31.19M shares derived: average of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | 31.03M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 30.70M shares derived: average of 2 quarters · filed 2025-03-20 | 30.34M shares derived: average of 3 quarters · filed 2025-03-20 | 30.03M shares 10-K · filed 2025-03-20 |
| 2023-09-30 | 30.37M shares 10-Q · filed 2024-11-13 | 29.99M shares derived: average of 2 quarters · filed 2024-11-13 | 29.70M shares 10-Q · filed 2024-11-13 | 28.90M shares derived: average of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | 29.61M shares 10-Q · filed 2024-08-08 | 29.36M shares 10-Q · filed 2024-08-08 | 28.41M shares derived: average of 3 quarters · filed 2024-08-08 | 27.06M shares derived: average of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | 29.09M shares 10-Q · filed 2024-05-07 | 27.80M shares derived: average of 2 quarters · filed 2024-05-07 | 26.21M shares derived: average of 3 quarters · filed 2024-05-07 | 25.31M shares derived: average of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | 26.51M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | 24.77M shares derived: average of 2 quarters · filed 2024-03-26 | 24.04M shares derived: average of 3 quarters · filed 2024-03-26 | 23.64M shares 10-K · filed 2024-03-26 |
| 2022-09-30 | 23.02M shares 10-Q · filed 2023-11-02 | 22.81M shares derived: average of 2 quarters · filed 2023-11-02 | 22.68M shares 10-Q · filed 2023-11-02 | 21.76M shares derived: average of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | 22.60M shares 10-Q · filed 2023-08-08 | 22.51M shares 10-Q · filed 2023-08-08 | 21.34M shares derived: average of 3 quarters · filed 2023-08-08 | 16.16M shares derived: average of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | 22.43M shares 10-Q · filed 2023-05-04 | 20.72M shares derived: average of 2 quarters · filed 2023-05-04 | 14.02M shares derived: average of 3 quarters · filed 2023-05-04 | 10.66M shares derived: average of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | 19.01M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | 9.81M shares derived: average of 2 quarters · filed 2023-03-23 | 6.74M shares derived: average of 3 quarters · filed 2023-03-23 | 5.19M shares 10-K · filed 2023-03-23 |
| 2021-09-30 | 611.68K shares 10-Q · filed 2022-11-14 | 602.56K shares derived: average of 2 quarters · filed 2022-11-14 | 585.32K shares 10-Q · filed 2022-11-14 | 573.12K shares derived: average of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | 593.43K shares 10-Q · filed 2022-08-09 | 571.92K shares 10-Q · filed 2022-08-09 | 560.27K shares derived: average of 3 quarters · filed 2022-08-09 | 554.53K shares derived: average of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | 550.17K shares 10-Q · filed 2022-05-11 | 543.69K shares derived: average of 2 quarters · filed 2022-05-11 | 541.56K shares derived: average of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | 537.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | 537.26K shares derived: average of 2 quarters · filed 2022-03-30 | 508.11K shares 10-K · filed 2022-03-30 | |
| 2020-09-30 | 537.32K shares 10-Q · filed 2021-11-17 | 498.42K shares 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |